Otsuka Subsidiary's Lung Cancer Drug Trial Meets Primary PFS Endpoint

MT Newswires Live

Aug 13

Otsuka (TYO:4578) subsidiary Taiho Pharmaceutical, its unit Taiho Oncology, and Cullinan Therapeutics' global Phase three Rezilient3 trial evaluating zipalertinib plus platinum-based chemotherapy met its primary endpoint of progression-free survival (PFS) at an interim analysis.

The trial enrolled adults with previously untreated, locally advanced or metastatic non-small cell lung cancer with previously untreated epidermal growth factor receptor exon 20 insertion-positive mutations, according to a Tokyo bourse filing on Thursday.

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics plan to seek approval for the combination as a first-line treatment, subject to discussions with the U.S. Food and Drug Administration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2659187021"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659187021\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659187021?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659187021","market":"sh","top_or_hot":-1,"title":"Otsuka Subsidiary's Lung Cancer Drug Trial Meets Primary PFS Endpoint","media":"MT Newswires Live","content":"<html><body><p> Otsuka (TYO:4578) subsidiary Taiho Pharmaceutical, its unit Taiho Oncology, and <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a>' global Phase three Rezilient3 trial evaluating zipalertinib plus platinum-based chemotherapy met its primary endpoint of progression-free survival (PFS) at an interim analysis.</p><p>The trial enrolled adults with previously untreated, locally advanced or metastatic non-small cell lung cancer with previously untreated epidermal growth factor receptor exon 20 insertion-positive mutations, according to a Tokyo bourse filing on Thursday.</p><p>Taiho Pharmaceutical, Taiho Oncology, and Cullinan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plan to seek approval for the combination as a first-line treatment, subject to discussions with the U.S. Food and Drug Administration.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Otsuka Subsidiary's Lung Cancer Drug Trial Meets Primary PFS Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOtsuka Subsidiary's Lung Cancer Drug Trial Meets Primary PFS Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-13 11:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Otsuka (TYO:4578) subsidiary Taiho Pharmaceutical, its unit Taiho Oncology, and <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a>' global Phase three Rezilient3 trial evaluating zipalertinib plus platinum-based chemotherapy met its primary endpoint of progression-free survival (PFS) at an interim analysis.</p><p>The trial enrolled adults with previously untreated, locally advanced or metastatic non-small cell lung cancer with previously untreated epidermal growth factor receptor exon 20 insertion-positive mutations, according to a Tokyo bourse filing on Thursday.</p><p>Taiho Pharmaceutical, Taiho Oncology, and Cullinan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plan to seek approval for the combination as a first-line treatment, subject to discussions with the U.S. Food and Drug Administration.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659187021","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659187021","pubTimestamp":1786591968,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Otsuka  subsidiary Taiho Pharmaceutical, its unit Taiho Oncology, and Cullinan Therapeutics' global Phase three Rezilient3 trial evaluating zipalertinib plus platinum-based chemotherapy met its primary endpoint of progression-free survival  at an interim analysis.The trial enrolled adults with previously untreated, locally advanced or metastatic non-small cell lung cancer with previously untreated epidermal growth factor receptor exon 20 insertion-positive mutations, according to a Tokyo bourse filing on Thursday.Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics plan to seek approval for the combination as a first-line treatment, subject to discussions with the U.S. Food and Drug Administration.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","BK4195":"互助储蓄与抵押信贷金融服务","PFS":"Provident Financial Services Inc"},"translate_title":"大冢子公司肺癌药物试验达到主要PFS终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFS":1.5},"content_text":"Otsuka (TYO:4578) subsidiary Taiho Pharmaceutical, its unit Taiho Oncology, and Cullinan Therapeutics' global Phase three Rezilient3 trial evaluating zipalertinib plus platinum-based chemotherapy met its primary endpoint of progression-free survival (PFS) at an interim analysis.The trial enrolled adults with previously untreated, locally advanced or metastatic non-small cell lung cancer with previously untreated epidermal growth factor receptor exon 20 insertion-positive mutations, according to a Tokyo bourse filing on Thursday.Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics plan to seek approval for the combination as a first-line treatment, subject to discussions with the U.S. Food and Drug Administration.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}